NO20091771L - Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat - Google Patents

Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat

Info

Publication number
NO20091771L
NO20091771L NO20091771A NO20091771A NO20091771L NO 20091771 L NO20091771 L NO 20091771L NO 20091771 A NO20091771 A NO 20091771A NO 20091771 A NO20091771 A NO 20091771A NO 20091771 L NO20091771 L NO 20091771L
Authority
NO
Norway
Prior art keywords
hydroxyethylcarbamate
chlorophenyl
crystal
fresh crystal
fresh
Prior art date
Application number
NO20091771A
Other languages
English (en)
Inventor
Matthew Peterson
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20091771L publication Critical patent/NO20091771L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)

Abstract

Foreliggende oppfinnelse vedrører en ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat, farmasøytiske sammensetninger omfattende denne krystall og fremgangsmåter for å fremstille og anvende denne krystall.
NO20091771A 2006-10-06 2009-05-05 Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat NO20091771L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82839206P 2006-10-06 2006-10-06
PCT/US2007/021502 WO2008045391A2 (en) 2006-10-06 2007-10-05 Novel crystal of (s)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate

Publications (1)

Publication Number Publication Date
NO20091771L true NO20091771L (no) 2009-05-05

Family

ID=39283405

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091771A NO20091771L (no) 2006-10-06 2009-05-05 Ny krystall av (S)-(+)-2-(2-klorfenyl)-2-hydroksyetylkarbamat

Country Status (19)

Country Link
US (1) US7632963B2 (no)
EP (1) EP2076258A4 (no)
JP (1) JP2010505856A (no)
KR (1) KR20090076958A (no)
CN (1) CN101657195A (no)
AU (1) AU2007307029A1 (no)
BR (1) BRPI0718131A2 (no)
CA (1) CA2665573A1 (no)
CO (1) CO6180504A2 (no)
CR (1) CR10764A (no)
EA (1) EA200970355A1 (no)
GT (1) GT200900076A (no)
IL (1) IL198016A0 (no)
MX (1) MX2009003755A (no)
NI (1) NI200900050A (no)
NO (1) NO20091771L (no)
SV (1) SV2009003211A (no)
WO (1) WO2008045391A2 (no)
ZA (1) ZA200903095B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
CN104870421A (zh) * 2011-12-27 2015-08-26 比皮艾思药物研发有限公司 用于预防或治疗als的苯基氨基甲酸酯化合物
EP4382509A1 (en) * 2021-08-05 2024-06-12 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate crystalline form and method for preparing same
KR102399807B1 (ko) * 2021-08-05 2022-05-20 (주)바이오팜솔루션즈 페닐카바메이트 결정형 및 이의 제조 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698588A (en) 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
WO2001019368A1 (en) * 1999-09-10 2001-03-22 Dainippon Ink And Chemicals, Inc. Quinolinone derivative preparations and process for producing the same
NZ527990A (en) * 2001-02-27 2006-01-27 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing or treating neurodegenerative disorders
AU2002358806B2 (en) * 2001-12-21 2009-09-10 Sk Biopharmaceuticals Co., Ltd. Process for preparing 2-(substituted phenyl)-2-hydroxy-ethyl carbamates
US7772240B2 (en) 2003-08-18 2010-08-10 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
RS51269B (sr) * 2004-09-16 2010-12-31 Janssen Pharmaceutica N.V. Upotreba 2-fenil-1,2-etandiol-(di)karbamata za tretiranje epileptogeneze
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection

Also Published As

Publication number Publication date
CN101657195A (zh) 2010-02-24
CR10764A (es) 2009-09-14
KR20090076958A (ko) 2009-07-13
ZA200903095B (en) 2010-07-28
WO2008045391A3 (en) 2008-06-12
US20080085930A1 (en) 2008-04-10
CA2665573A1 (en) 2008-04-17
BRPI0718131A2 (pt) 2013-11-05
WO2008045391A2 (en) 2008-04-17
MX2009003755A (es) 2009-07-10
EA200970355A1 (ru) 2009-12-30
AU2007307029A1 (en) 2008-04-17
EP2076258A4 (en) 2011-09-28
SV2009003211A (es) 2009-11-24
IL198016A0 (en) 2009-12-24
JP2010505856A (ja) 2010-02-25
EP2076258A2 (en) 2009-07-08
CO6180504A2 (es) 2010-07-19
US7632963B2 (en) 2009-12-15
GT200900076A (es) 2010-05-18
NI200900050A (es) 2010-02-01

Similar Documents

Publication Publication Date Title
EA201000642A1 (ru) 2'-фтор-2'-дезокситетрагидроуридины в качестве ингибиторов цитидиндеаминазы
EA201070786A1 (ru) Бензофуропиримидиноны
PH12014500053A1 (en) Proteasome inhibitors
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
NO20092637L (no) Fremgangsmater for behandling
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
NO20092584L (no) Farmasoytiske sammensetninger og deres fremgangsmater for anvendelse
CY1112653T1 (el) Κρυσταλλικες τροποποιησεις της πυρακλοστροβινης
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
EA200970156A1 (ru) Пиридизиноновые производные
EA200800760A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
NO20090596L (no) Antivirale fosfinatforbindelser
TW200621721A (en) Methods of preparing indazole compounds
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
EA201170703A1 (ru) Производные адамантилбензамида
DK3072507T3 (da) Farmaceutiske sammensætninger til glukokortikoidsubstitutionsterapi
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
EA201070424A1 (ru) Хиназолиндионовые производные, их получение и их применения в терапии
EA200801414A1 (ru) Кальцилитические соединения
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application